‘Bond market tantrum risks’: Gilt traders brace for Labour leftward pivot as Starmer future uncertain
London Tech Week: Astrazeneca’s AI push could take humans out of the loop June 10, 2025 Astrazeneca unveiled an ambitious overhaul of its manufacturing and supply operations driven by deep tech, AI, and what it called a “self-healing” supply chain at London Tech Week. The firm claimed it’s laying the groundwork to become one of the top 10 most innovative and sustainable supply chains globally by 2030. But while the vision [...]
GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs April 30, 2025 British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]
FTSE 100 slumps as EU and China launch retaliatory tariffs against US April 9, 2025 The FTSE 100 closed in the red on Wednesday, reversing gains made at the start of the week. The blue-chip index was off 2.9 per cent. Pharma stocks drove losses on the back of fresh tariff threats from President Donald Trump. Astrazeneca closed off seven per cent and GSK 5.7 per cent. Lenders also suffered [...]
Astrazeneca, BP, HSBC: The FTSE 100 stocks hit by Trump and China’s trade war April 9, 2025 The global trade war has kicked into a new gear and it’s bad news for some of the FTSE 100’s biggest firms. Numerous giants on the UK’s flagship index have significant exposure to Asia and more importantly one of Trumps biggest targets – China. The White House has been relentless in its trade offensive on [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
Astrazeneca cancels £450m vaccine plant, blaming state funding cut January 31, 2025 Astrazeneca has cancelled a planned £450m investment in a vaccine manufacturing plant in Merseyside, saying Labour have failed to match the previous government’s offer of funding. It sees the pharmaceutical firm scrap plans to expand its existing facility in Speke, as announced by then-chancellor Jeremy Hunt at last year’s March budget, as first reported by [...]
Astrazeneca: How a fraud investigation crashed a FTSE 100 giant November 10, 2024 Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal Soriot’s strategic overhaul over the past decade, which has steered Astrazeneca away from its historic focus on respiratory and primary care toward a successful [...]
KPMG and Natwest put the CBI back in business October 9, 2024 Companies renew their memberships to CBI offering hope for the firm's continuation
Astrazeneca boosts cardiovascular pipeline with licensing deal October 7, 2024 Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.